Gilead Sciences: The Turnaround Is Here, Finally!
Gilead Sciences continues a recent trend with limited revenue growth in Q3.
The biotech has the pipeline to generate decent growth over the next 5 years.
A boost to the capital returns could yield a 4% dividend and 10% EPS growth.
For years, Gilead Sciences (GILD) has been plagued by declining sales form their crucial HCV drug franchise causing a painful few years for shareholders. The stock topped $120 back in 2014 and the company finally appears poised for a sustainable turnaround, albeit a minor one.
Read the full article on Seeking Alpha.
Disclosure: Long GILD. Please review the disclaimer page for more details.